SCHEMBL20239333

SCHEMBL20239333

CCc1nc(CNc2ncc(Cl)cn2)cc(Oc2ccc(CS(=O)(=O)NC)cc2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.56
SMN1; SMN2 Q16637 2/20 0.37
KDM4E B2RXH2 1/20 0.37
PDE4B Q07343 2/20 0.35
RAB9A P51151 2/20 0.34
ALDH1A1 P00352 1/20 0.34
VNN1 O95497 1/20 0.33
CYP3A4 P08684 1/20 0.33
PTGS1 P23219 2/20 0.32
PTGS2 P35354 2/20 0.32
CYP2C9 P11712 1/20 0.32
NPC1 O15118 1/20 0.31
MAPT P10636 2/20 0.31
HPGD P15428 1/20 0.31
MET P08581 1/20 0.31
KDR P35968 1/20 0.31
P2RX3 P56373 1/20 0.31
ALOX15 P16050 1/20 0.31
CYP17A1 P05093 1/20 0.31
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16738674 0.89 DGAT2 (0.57) DGAT2SMN1; SMN2KDM4EPDE4BRAB9A
SCHEMBL20239203 0.89 DGAT2 (0.59) DGAT2SMN1; SMN2KDM4EPDE4BRAB9A
SCHEMBL20239171 0.88 DGAT2 (0.56) DGAT2SMN1; SMN2KDM4EPDE4BRAB9A
SCHEMBL20239227 0.88 DGAT2 (0.56) DGAT2SMN1; SMN2KDM4EVNN1CYP3A4
SCHEMBL20239176 0.87 DGAT2 (0.55) DGAT2SMN1; SMN2KDM4ERAB9AALDH1A1
SCHEMBL20239169 0.86 DGAT2 (0.54) DGAT2SMN1; SMN2KDM4EALDH1A1VNN1
SCHEMBL18249757 0.86 DGAT2 (0.54) DGAT2SMN1; SMN2KDM4EVNN1P2RX3
SCHEMBL20239272 0.85 DGAT2 (0.55) DGAT2SMN1; SMN2KDM4EPDE4BVNN1
SCHEMBL20239325 0.85 DGAT2 (0.45) DGAT2SMN1; SMN2RAB9AVNN1NPC1
SCHEMBL20239182 0.83 DGAT2 (0.47) DGAT2SMN1; SMN2RAB9AALDH1A1VNN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT DGAT2 1/4885SMN1; SMN2 4828/4885KDM4E 4070/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT DGAT2 1/4885SMN1; SMN2 4835/4885KDM4E 3891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.